Heidelberg Pharma AG (0QW5.L)
| Previous close | 6.81 |
| Open | 6.77 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 6.69 - 6.77 |
| 52-week range | 6.69 - 6.77 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 172.468M |
| Beta (5Y monthly) | -0.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.66 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- EQS Group
Heidelberg Pharma Participates at Various Conferences
DGAP-News: Heidelberg Pharma AG / Key word(s): Conference28.10.2021 / 12:38 The issuer is solely responsible for the content of this announcement.PRESS RELEASEHeidelberg Pharma Participates at Various Conferences Ladenburg, Germany, 28 October 2021 - Heidelberg Pharma AG (FSE: HPHA) will present the company and its proprietary ATAC technology at several upcoming scientific and investor conferences. Heidelberg Pharma uses Amanitin as an innovative toxin to develop new cancer therapies that, when
- EQS Group
Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2021
DGAP-News: Heidelberg Pharma AG / Key word(s): Quarterly / Interim Statement07.10.2021 / 06:59 The issuer is solely responsible for the content of this announcement.Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2021- Paul-Ehrlich-Institut follows the FDA in giving clearance to begin a Phase I/IIa trial of HDP-101; first trial centers initiated in the USA- Gross issue proceeds of over EUR 20 million generated from private placement in June- Significant advances ma
- EQS Group
Heidelberg Pharma AG Announces Adjustment of Guidance
Heidelberg Pharma AG / Key word(s): ForecastHeidelberg Pharma AG Announces Adjustment of Guidance01-Oct-2021 / 13:49 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Ad hoc announcement - Inside information pursuant to Article 17 MARHeidelberg Pharma AG Announces Adjustment of GuidanceLadenburg, Germany, 1 October 2021 - Heide
